Mobia Medical (NASDAQ:MOBI – Get Free Report)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report released on Tuesday, Benzinga reports. They presently have a $19.00 target price on the stock. BTIG Research‘s price target suggests a potential upside of 79.58% from the company’s current price.
A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Weiss Ratings began coverage on shares of Mobia Medical in a research report on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mobia Medical currently has an average rating of “Moderate Buy” and a consensus target price of $20.75.
View Our Latest Stock Analysis on Mobia Medical
Mobia Medical Price Performance
Shares of Mobia Medical stock opened at $10.58 on Tuesday. The firm has a market cap of $352.21 million and a PE ratio of -0.52. The company has a quick ratio of 12.80, a current ratio of 13.28 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average price is $10.08. Mobia Medical has a 12-month low of $8.03 and a 12-month high of $15.29.
Mobia Medical (NASDAQ:MOBI – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million for the quarter. The company’s revenue for the quarter was up 102.4% on a year-over-year basis. On average, equities analysts anticipate that Mobia Medical will post -2.63 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Casey Tansey acquired 16,441 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $12.07 per share, with a total value of $198,442.87. Following the acquisition, the director directly owned 318,332 shares in the company, valued at $3,842,267.24. The trade was a 5.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have bought 87,000 shares of company stock worth $1,016,367.
Institutional Investors Weigh In On Mobia Medical
A number of hedge funds have recently added to or reduced their stakes in MOBI. State Street Corp bought a new stake in Mobia Medical during the 2nd quarter worth about $735,000. Citadel Advisors LLC bought a new stake in Mobia Medical during the 2nd quarter worth about $670,000. Finally, Readystate Asset Management LP bought a new stake in Mobia Medical during the 2nd quarter worth about $134,000.
About Mobia Medical
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Read More
- Five stocks we like better than Mobia Medical
- WD-40 Could Reward Patient Investors—Here’s Why
- NextEra and Dominion Have a Deal—Now Comes the Hard Part
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
Receive News & Ratings for Mobia Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobia Medical and related companies with MarketBeat.com's FREE daily email newsletter.
